- Price
- $261.62
- Day
- +3.99%
- Mkt Cap
- $16.43B
- 52W Range
- $105.00 – $262.00
- Volume
- 1.87M
- Beta
- 0.36
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) on Monday reported better-than-expected second-quarter sales results and raised its FY26 sales guidance above estimates.
Read full article
Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
Read full article
Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript
Read full article
Jazz Pharmaceuticals NASDAQ: JAZZ reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly sales. The company raised its full-year revenue outlook and said it is preparing for a potential August approval and launch of zanidatamab in first-line HER2-positive metastatic gastroesophageal adenocarcinoma, or GEA.
Read full article
– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company raises 2026 revenue guidance – – Prepared to launch Ziihera® in HER2+ 1L GEA immediately following FDA approval – – Xywav® revenues grew 13% YoY with 525 net patient adds in 2Q26 – – Epidiolex® revenues grew 16% YoY – DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026. "Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.
Read full article
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $6.04 per share. This compares to a loss of $8.25 per share a year ago.
Read full article
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return of 6.92% pure gross of fees (6.40% net of fees), underperforming the MSCI ACWI Index, which returned 14.93%, and the MSCI World Index, which returned 13.76%. During the quarter, we sold our positions in Danaher, Dolby Laboratories, and Tokyo Century and purchased Techtronic Industries and Wal-Mart de Mexico. Munich Re, the world's largest reinsurance company, was a detractor during the quarter.
Read full article
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read full article
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
Read full article
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Read full article